Ro to offer lower-price vials of weight loss drug Zepbound

Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
It is made possible through a first-of-a-kind integration with Eli Lilly's direct-to-consumer website, and aims to streamline access to the popular treatment.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Is Zepbound or Wegovy Better for Weight Loss? One Can Help You Shed 50 Lbs
With so many weight loss medications on the market, it’s easy to feel overwhelmed by the options. From brand-name heavy hitters to compounded varieties, each promises to help shed pounds. But a recent head-to-head trial comparing Zepbound vs.
Zepbound brings more weight loss than Wegovy: Drugmaker
Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from their SURMOUNT-5 phase clinical trial on Wednesday which is the first time both GLP1s have been compared side-by-side.
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Zepbound Leads to More Weight Loss Than Wegovy in Head-to-Head Clinical Trial
Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a clinical trial show 20% of participants who took Zepbound achieved significant weight loss compared to nearly 14% of participants who took Wegovy.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
Weed and Weight Loss?
Cannabis might help with weight loss by targeting the endocannabinoid system, potentially suppressing appetite, boosting metabolism, and offering new, less invasive treatments for obesity and
Zepbound Vs. Wegovy: Which Is Better for Weight Loss?
For the uninitiated, both Zepbound (tirzepatide) and Wegovy (semaglutide) are weight loss drugs. They target hormones that influence metabolism and appetite, but they operate through different mechanisms.
Weight loss drug fill rates, by state
To assess state-level trends, GoodRx examined fill rates for all medications, excluding vaccines, from a nationally representative sample between Jan. 1 and Oct. 31. The figures below reflect the percentage of total medication fills for GIP and GLP-1 drugs prescribed for either diabetes or weight loss indications.
Fierce Healthcare6h
Ro teams up with Eli Lilly to offer single-dose vials of weight loss drug Zepbound
Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...
Zepbound users discuss weight loss after preliminary research touts effectiveness
A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s ...
Crain's New York4h
Eli Lilly taps Ro to help it sell a cheaper version of its weight-loss drug
Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...
Which Weight-Loss Drug Is Better: Wegovy or Zepbound?
With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...
STAT23h
Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.